J. M. Molina, C. Capitant, B. Spire, G. Pialoux, L. Cotte et al., On-demand preexposure prophylaxis in men at high risk for HIV-1 infection, ANRS IPERGAY Study Group, vol.373, pp.2237-2246, 2015.
URL : https://hal.archives-ouvertes.fr/halshs-01429281

. Fda and . Fda, Press release: FDA approves first drug for reducing the risk of sexually acquired HIV infection, 2012.

C. Hankins, R. Macklin, and M. Warren, Translating PrEP effectiveness into public health impact: key considerations for decisionmakers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access, J Int AIDS Soc, vol.18, issue.4, 2015.

J. L. Juusola, M. L. Brandeau, D. K. Owens, and E. Bendavid, The costeffectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men, Ann Intern Med, vol.156, pp.541-550, 2012.

G. B. Gomez, A. Borquez, K. K. Case, A. Wheelock, A. Vassall et al., The cost and impact of scaling up preexposure prophylaxis for HIV prevention: a systematic review of costeffectiveness modelling studies, PLoS Med, vol.10, p.1001401, 2013.

B. E. Nichols, C. A. Boucher, M. Van-der-valk, B. J. Rijnders, and D. A. Van-de-vijver, Cost-effectiveness analysis of preexposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study, Lancet Infect Dis, vol.16, pp.1423-1429, 2016.

E. Ouellet, M. Durand, J. R. Guertin, J. Lelorier, and C. L. Tremblay, Cost effectiveness of 'on-demand' HIV preexposure prophylaxis for noninjection drug-using men who have sex with men in Canada, Can J Infect Dis Med Microbiol, vol.26, pp.23-29, 2015.

F. J. Hellinger, Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US, Pharmacoeconomics, vol.31, pp.1091-1104, 2013.

M. L. Kamb, M. Fishbein, J. M. Douglas, F. Rhodes, J. Rogers et al., Project RESPECT study group. Efficacy of risk reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized trial, JAMA, vol.280, pp.1161-1167, 1998.

D. Husereau, M. Drummond, S. Petrou, C. Carswell, D. Moher et al., ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS): explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force, Value Health, vol.16, pp.231-250, 2013.

C. E. Sloan, K. Champenois, P. Choisy, E. Losina, R. P. Walensky et al., Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults, AIDS, vol.26, pp.45-56, 2012.

T. D. Hollingsworth, R. M. Anderson, and C. Fraser, HIV-1 transmission, by stage of infection, J Infect Dis, vol.198, pp.687-693, 2008.

R. F. Baggaley, R. G. White, and M. C. Boily, HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention, Int J Epidemiol, vol.39, pp.1048-1063, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00587268

A. Velter, F. Barin, A. Bouyssou, J. Guinard, L. Léon et al., HIV prevalence and sexual risk behaviors associated with awareness of HIV status among men who have sex with men in, AIDS Behav, vol.17, pp.1266-1278, 2013.

N. Punyacharoensin, W. J. Edmunds, D. Angelis, D. Delpech, V. Hart et al., Modelling the HIV epidemic among MSM in the United Kingdom: quantifying the contributions to HIV transmission to better inform prevention initiatives, AIDS, vol.29, pp.339-349, 2015.

N. Punyacharoensin, W. J. Edmunds, D. Angelis, D. Delpech, V. Hart et al., Effect of preexposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study, Lancet HIV, vol.3, pp.94-104, 2016.

D. H. Lee and O. Vielemeyer, Correspondence: preexposure chemoprophylaxis for HIV prevention, N Engl J Med, vol.364, pp.1372-1375, 2011.

F. Lin, P. G. Farnham, R. K. Shrestha, J. Mermin, and S. L. Sansom, Cost effectiveness of HIV prevention interventions in the U.S, Am J Prev Med, vol.50, pp.699-708, 2016.

A. Chen and D. W. Dowdy, Clinical effectiveness and cost-effectiveness of HIV preexposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making, PLoS One, vol.9, p.108742, 2014.

S. B. Keller and D. M. Smith, The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of preexposure prophylaxis, AIDS, vol.25, pp.2308-2310, 2011.

K. J. Ong, S. Desai, and S. Desai, Will HIV PrEP given to high-risk MSM in England be cost-effective? Preliminary results of a static decision analytical model, Public Health England Conference, 2015.

R. T. Koppenhaver, S. W. Sorensen, P. G. Farnham, and S. L. Sansom, The cost-effectiveness of preexposure prophylaxis in men who have sex with men in the United States: an epidemic model, J Acquir Immune Defic Syndr, vol.58, pp.51-52, 2011.

V. Cambiano, M. Al, and A. Phillips, What do we know about the cost-effectiveness of HIV preexposure prophylaxis, and is it affordable?, Curr Opin HIV AIDS, vol.11, pp.56-66, 2016.

E. L. Ross, S. K. Cinti, and D. W. Hutton, Implementation and operational research: a cost-effective, clinically actionable strategy for targeting HIV preexposure prophylaxis to high-risk men who have sex with men, J Acquir Immune Defic Syndr, vol.72, pp.61-67, 2016.